Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee

[In The News]

-- Inclusion in the "Best of The Liver Meeting's Summary" is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB -- In patients with the baseline HBsAg level ≤ 500 IU/mL, the Phase IIb study demonstrated sustained HBsAg...

View the full article